Home/Indications/CNS/Parkinson's Disease

Parkinson's Disease

CNS 3 original drugs

Novel Drugs

Reformulations

Drug Targets

CNS indication. Parkinson's Disease has 3 FDA-approved novel treatments, led by KYOWA KIRIN, with 185 active industry clinical trials across 14 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Parkinson's Disease Market Leaders

Companies with the most FDA-approved novel Parkinson's Disease drugs.

Phase 3 Readouts Pro

8 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q3 2026

CVN424 75 mg

Cerevance

Estimated · fresh NCT06553027

Q1 2027

HRG2010; Sustained-release Carbidopa/Levodopa administered placebo

Jiangsu HengRui Medicine Co., Ltd.

Estimated · stale NCT06596876

Q1 2027

bemdaneprocel

BlueRock Therapeutics

Estimated · fresh NCT06944522

Unlock 5 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Parkinson's Disease Treatments by Mechanism

Top 11 mechanisms across 26 industry trials with a known mechanism of action.

See full pipeline →

Nonergot Dopamine Agonist

10 trials 4 sponsors

Catechol-O-Methyltransferase Inhibitor

4 trials 2 sponsors

Dopa-decarboxylase

2 trials 1 sponsor

Adenosine A2A receptor

2 trials 1 sponsor

Aromatic Amino Acid Decarboxylation Inhibitor

2 trials 2 sponsors

D2 receptor/D3 receptor/D4 receptor/D5 receptor/α1D receptor/α2B receptor/α2C receptor

1 trials 1 sponsor

Peroxisome Proliferator Receptor alpha Agonist

1 trials 1 sponsor

Iron Chelator

1 trials 1 sponsor

Cholinergic Nicotinic Agonist

1 trials 1 sponsor

Atypical Antipsychotic

1 trials 1 sponsor

Benzodiazepine

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Parkinson's Disease Clinical Pipeline by Phase

504 industry-sponsored trials across 199 sponsors

View full landscape →

Showing 27 of 27 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Impax Laboratories, LLC	CREXONT ER	—	RECRUITING	2025-11	NCT06765668
Bial - Portela C S.A.	Opicapone 50 mg	—	COMPLETED	2024-02-16	NCT04986982
Eisai Korea Inc.	Safinamide Mesilate	—	COMPLETED	2023-05-25	NCT05312632
Bial - Portela C S.A.	Opicapone	Catechol-O-Methyltransferase Inhibitor [EPC]	COMPLETED	2023-04-04	NCT04990284
Bial - Portela C S.A.	Opicapone	Catechol-O-Methyltransferase Inhibitor [EPC]	COMPLETED	2023-03-29	NCT04986995
SK Chemicals Co., Ltd.	Ongentys 50mg	—	COMPLETED	2022-08-18	NCT04821687
ACADIA Pharmaceuticals Inc.	Pimavanserin	—	COMPLETED	2022-04-26	NCT04292223
Zambon SpA	Safinamide Methanesulfonate	—	COMPLETED	2021-04-30	NCT03841604
Boehringer Ingelheim	Pramipexole SR	—	COMPLETED	2020-01-07	NCT03521635
Bial - Portela C S.A.	BIA 9-1067	—	COMPLETED	2018-07-04	NCT02847442
Novartis	pramipexole	—	COMPLETED	2016-05-23	NCT01673724
Teva Branded Pharmaceutical Products R&D, Inc.	Rasagiline	—	COMPLETED	2015-01	NCT01723228
GSK	ropinirole/L-dopa	—	COMPLETED	2014-11-18	NCT01494532
UCB Korea Co., Ltd.	Rotigotine	Nonergot Dopamine Agonist [EPC]	COMPLETED	2014-10	NCT01523301
GSK	ropinirole monotherapy	—	COMPLETED	2014-04-30	NCT01485172
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals	APOKYN	—	COMPLETED	2014-04	NCT01770145
UCB BIOSCIENCES GmbH	Rotigotine	Nonergot Dopamine Agonist [EPC]	COMPLETED	2014-01	NCT01782222
UCB BIOSCIENCES GmbH	Rotigotine	Nonergot Dopamine Agonist [EPC]	COMPLETED	2013-12	NCT01744496
MedtronicNeuro	—	—	COMPLETED	2013-07	NCT00998660
UCB BIOSCIENCES GmbH	Rotigotine	Nonergot Dopamine Agonist [EPC]	COMPLETED	2013-03	NCT01711866
Teva Neuroscience, Inc.	Rasagiline	—	COMPLETED	2012-10	NCT01049984
UCB Pharma	Rotigotine	Nonergot Dopamine Agonist [EPC]	COMPLETED	2012-10	NCT01300819
Lundbeck Italia S.p.A.	Rasagiline	—	COMPLETED	2012-07	NCT01055379
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals	APOKYN	—	TERMINATED	2016-12	NCT02549573
UCB Pharma SA	—	—	TERMINATED	2012-12	NCT01519882
Novartis	Carbidopa/levodopa/entacapone	—	TERMINATED	2009-05	NCT00642356
Novartis	carbidopa/levodopa	—	WITHDRAWN	2009-11	NCT00601978

Showing 100 of 109 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
BlueRock Therapeutics	bemdaneprocel	—	RECRUITING	2027-03	NCT06944522
Biohaven Therapeutics Ltd.	BHV-8000	—	RECRUITING	2027-08	NCT06976268
Roche	Prasinezumab	—	RECRUITING	2029-06-30	NCT07174310
Annovis Bio Inc.	buntanetap/posiphen	—	RECRUITING	2029-09	NCT07284784
Cerevance	CVN424 75 mg	—	ACTIVE NOT RECRUITING	2026-08	NCT06553027
NeuroDerm Ltd.	Oral IR-LD/CD	—	ACTIVE NOT RECRUITING	2022-11-01	NCT04006210
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals	apomorphine infusion	—	ACTIVE NOT RECRUITING	2018-12	NCT02339064
AbbVie	ABBV-951	—	COMPLETED	2026-04-27	NCT04750226
AbbVie	ABBV-951	—	COMPLETED	2026-04-17	NCT04379050
Tasly Pharmaceutical Group Co., Ltd	pimavanserin tartrate	—	COMPLETED	2026-02-01	NCT06068465
AbbVie	Tavapadon	—	COMPLETED	2025-12-01	NCT04760769
Jiangsu HengRui Medicine Co., Ltd.	HRG2010; Sustained-release Carbidopa/Levodopa administered placebo	—	COMPLETED	2025-10-09	NCT06596876
AbbVie	Tavapadon	—	COMPLETED	2024-10-01	NCT04223193
GE Healthcare	SPECT	—	COMPLETED	2024-08-02	NCT04265209
AbbVie	Tavapadon	—	COMPLETED	2024-06-28	NCT04201093
AbbVie	Tavapadon	—	COMPLETED	2024-01-29	NCT04542499
Annovis Bio Inc.	buntanetap/posiphen	—	COMPLETED	2023-12-04	NCT05357989
Sumitomo Pharma America, Inc.	APL-130277	—	COMPLETED	2022-11-08	NCT02542696
AbbVie	ABBV-951	—	COMPLETED	2022-08-17	NCT03781167
Impax Laboratories, LLC	IPX203	—	COMPLETED	2022-03-21	NCT03877510
Luye Pharma Group Ltd.	LY03003(Rotigotine,extended-release microspheres)	—	COMPLETED	2022-03-17	NCT04571164
GE Healthcare	DaTSCAN™ Ioflupane (123I) Injection	—	COMPLETED	2021-12-20	NCT04193527
AbbVie	Levodopa-Carbidopa Intestinal Gel (LCIG)	—	COMPLETED	2021-11-30	NCT00660673
AbbVie	ABBV-951	—	COMPLETED	2021-09-29	NCT04380142
Pharma Two B Ltd.	P2B001 0.6/0.75 mg	—	COMPLETED	2021-08-23	NCT03329508
Zambon SpA	Safinamide	—	COMPLETED	2021-08-20	NCT03881371
Sumitomo Pharma America, Inc.	APL-130277	—	COMPLETED	2021-08-11	NCT03391882
Impax Laboratories, LLC	IR CD-LD	—	COMPLETED	2021-06-15	NCT03670953
AbbVie	Optimized Medical Treatment	—	COMPLETED	2020-05-14	NCT02549092
AbbVie	ABT-SLV187	—	COMPLETED	2019-10-31	NCT02082249
AbbVie	Optimized antiparkinsonian treatment	—	COMPLETED	2019-09-19	NCT02799381
Acorda Therapeutics	CVT-301	—	COMPLETED	2018-05	NCT02242487
Adamas Pharmaceuticals, Inc.	ADS-5102	—	COMPLETED	2018-02	NCT02202551
Kyowa Kirin Co., Ltd.	Istradefylline 20 mg or 40 mg	—	COMPLETED	2017-12-20	NCT02610231
Sumitomo Pharma America, Inc.	APL-130277	—	COMPLETED	2017-12-11	NCT02469090
Acorda Therapeutics	CVT-301	—	COMPLETED	2017-05	NCT02352363
Takeda	TVP-1012 1mg	—	COMPLETED	2017-03-14	NCT02337751
Acorda Therapeutics	CVT-301 Low Dose	—	COMPLETED	2016-12	NCT02240030
Kyowa Kirin Co., Ltd.	Istradefylline 40 mg	—	COMPLETED	2016-10	NCT01968031
Takeda	TVP-1012 1mg	—	COMPLETED	2016-09-29	NCT02337764
Takeda	TVP-1012 1mg	—	COMPLETED	2016-09-17	NCT02337738
Takeda	TVP-1012	—	COMPLETED	2016-09-15	NCT02337725
Britannia Pharmaceuticals Ltd.	Apomorphine hydrochloride	D2 receptor/D3 receptor/D4 receptor/D5 receptor/α1D receptor/α2B receptor/α2C receptor	COMPLETED	2016-06-06	NCT02006121
Adamas Pharmaceuticals, Inc.	ADS-5102	—	COMPLETED	2016-03-10	NCT02274766
Avid Radiopharmaceuticals	18F-AV-133	—	COMPLETED	2016-03	NCT01550484
Adamas Pharmaceuticals, Inc.	ADS-5102	—	COMPLETED	2015-12	NCT02136914
Merz Pharmaceuticals GmbH	IncobotulinumtoxinA (100 Units)	—	COMPLETED	2015-08	NCT02091739
Pharma Two B Ltd.	P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),	—	COMPLETED	2015-05	NCT01968460
AbbVie (prior sponsor, Abbott)	Levodopa-Carbidopa Intestinal Gel	—	COMPLETED	2015-03	NCT01736176
AbbVie	Levodopa-carbidopa intestinal gel	—	COMPLETED	2015-03	NCT01960842
UCB Pharma	Rotigotine	Nonergot Dopamine Agonist [EPC]	COMPLETED	2014-10	NCT01646255
UCB Pharma	Rotigotine	Nonergot Dopamine Agonist [EPC]	COMPLETED	2014-05	NCT01646268
H. Lundbeck A/S	rasagiline	—	COMPLETED	2013-12	NCT01556165
Bial - Portela C S.A.	BIA 9-1067	—	COMPLETED	2013-11	NCT01568073
Mundipharma Research GmbH & Co KG	Oxycodone/Naloxone Prolonged Release tablets	—	COMPLETED	2013-08	NCT01439100
H. Lundbeck A/S	Azilect®	—	COMPLETED	2013-06	NCT01479530
Adamas Pharmaceuticals, Inc.	ADS-5102 (extended release amantadine HCl)	—	COMPLETED	2013-05	NCT01397422
Merck	Preladenant	—	COMPLETED	2013-04-04	NCT01227265
Impax Laboratories, LLC	IPX066	—	COMPLETED	2013-03	NCT01411137
UCB BIOSCIENCES GmbH	Rotigotine	Nonergot Dopamine Agonist [EPC]	COMPLETED	2013-03	NCT01723904
Merck	Preladenant 2 mg tablet	—	COMPLETED	2012-12-20	NCT01155466
ACADIA Pharmaceuticals Inc.	pimavanserin tartrate	—	COMPLETED	2012-11	NCT01174004
Biotie Therapies Inc.	Tozadenant (SYN115) 60 mg BID	—	COMPLETED	2012-10	NCT01283594
AbbVie (prior sponsor, Abbott)	Levodopa-carbidopa intestinal gel	—	COMPLETED	2012-10	NCT00360568
Chelsea Therapeutics	Droxidopa	Dopa-decarboxylase	COMPLETED	2012-10	NCT01176240
Bial - Portela C S.A.	BIA 9-1067	—	COMPLETED	2012-07	NCT01227655
AbbVie (prior sponsor, Abbott)	Levodopa-carbidopa intestinal gel	—	COMPLETED	2012-06	NCT00335153
Otsuka Pharmaceutical Co., Ltd.	SPM 962	—	COMPLETED	2012-06	NCT01631825
H. Lundbeck A/S	Azilect®	—	COMPLETED	2012-06	NCT01268891
GSK	Requip PR	—	COMPLETED	2012-03-01	NCT01536574
Impax Laboratories, LLC	IPX066	—	COMPLETED	2012-01	NCT01130493
Boehringer Ingelheim	pramipexole immediate release tablet	—	COMPLETED	2012-01	NCT01191944
Newron Pharmaceuticals SPA	Safinimide 50-100 mg/day	—	COMPLETED	2012-01	NCT00627640
Desitin Arzneimittel GmbH	piribedil	—	COMPLETED	2011-12	NCT01007864
Impax Laboratories, LLC	IPX066 95 mg	—	COMPLETED	2011-10	NCT01096186
AbbVie (prior sponsor, Abbott)	Levodopa carbidopa intestinal gel (LCIG)	—	COMPLETED	2011-10	NCT00660387
AbbVie (prior sponsor, Abbott)	Levodopa carbidopa intestinal gel (LCIG)	—	COMPLETED	2011-10	NCT00357994
GSK	ReQuip PR	—	COMPLETED	2011-09-01	NCT01154166
Kyowa Kirin Co., Ltd.	Istradefylline	Adenosine A2A receptor	COMPLETED	2011-09	NCT00957203
Kyowa Kirin Co., Ltd.	KW-6500	—	COMPLETED	2011-08	NCT01063621
Otsuka Pharmaceutical Co., Ltd.	SPM 962	—	COMPLETED	2011-05	NCT01628926
Catalysis SL	—	—	COMPLETED	2011-05	NCT01016470
Kyowa Kirin Co., Ltd.	Istradefylline	Adenosine A2A receptor	COMPLETED	2011-02	NCT00955526
Impax Laboratories, LLC	IPX066	—	COMPLETED	2011-01	NCT00974974
Kyowa Kirin Co., Ltd.	KW-6500	—	COMPLETED	2010-12	NCT00955318
GSK	ropinirole PR/XR	—	COMPLETED	2010-12	NCT00823836
Novartis	Rivastigmine capsule	—	COMPLETED	2010-11	NCT00623103
Impax Laboratories, LLC	IPX066 95 mg LD	—	COMPLETED	2010-10	NCT00880620
Kyowa Kirin Co., Ltd.	KW-6500	—	COMPLETED	2010-10	NCT01058291
Otsuka Pharmaceutical Co., Ltd.	SPM 962	—	COMPLETED	2010-10	NCT01628965
Boehringer Ingelheim	Pramipexole	—	COMPLETED	2010-06	NCT00601523
ACADIA Pharmaceuticals Inc.	Pimavanserin tartrate (ACP-103)	—	COMPLETED	2009-12	NCT00658567
Biogen	BIIB122	—	TERMINATED	2023-07-27	NCT05418673
Addex Pharma S.A.	Dipraglurant	—	TERMINATED	2022-06-17	NCT04857359
Addex Pharma S.A.	Dipraglurant	—	TERMINATED	2022-06-17	NCT05116813
Theravance Biopharma	ampreloxetine	—	TERMINATED	2021-11-10	NCT03829657
Biotie Therapies Inc.	Tozadenant	—	TERMINATED	2018-01-16	NCT03051607
Biotie Therapies Inc.	tozadenant	—	TERMINATED	2018-01-12	NCT02453386
Adamas Pharmaceuticals, Inc.	amantadine HCl ER	—	TERMINATED	2016-05-20	NCT02153632
Adamas Pharmaceuticals, Inc.	240mg Amantadine HCl ER tablets	—	TERMINATED	2016-05-20	NCT02153645

Showing 100 of 193 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)	18F-MFBG	—	RECRUITING	2026-09-30	NCT07176286
Hillhurst Biopharmaceuticals, Inc.	HBI-002	—	RECRUITING	2026-12-31	NCT07005180
Gateway Institute for Brain Research	INS-GSH	—	RECRUITING	2027-01-01	NCT05266417
GEN İlaç ve Sağlık Ürünleri A.Ş.	SUL-238 (1500 mg t.i.d.) film-coated tablets	—	RECRUITING	2027-03-01	NCT07322887
Integrative Research Laboratories AB	IRL757	—	RECRUITING	2027-05	NCT07461220
iRegene Therapeutics Co., Ltd.	Human Dopaminergic Progenitor Cells	—	RECRUITING	2027-09	NCT07102342
Appello Pharmaceuticals, Inc.	AP-472	—	RECRUITING	2027-09-03	NCT07432958
Neuron23 Inc.	NEU-411	—	RECRUITING	2027-12	NCT06680830
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.	human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection	—	RECRUITING	2028-03-30	NCT07166757
AskBio Inc	AAV2-GDNF gene therapy	—	RECRUITING	2028-08-31	NCT06285643
Sumitomo Pharma America, Inc.	—	—	RECRUITING	2030-12-15	NCT06753331
Guangzhou Novaken Pharm Co., Ltd.	XJN010 Nasal Spray	—	RECRUITING	2026-03-30	NCT07156773
U: The Mind Company	—	—	RECRUITING	2026-03-01	NCT07182058
Ashvattha Therapeutics, Inc.	18F-OP-801	—	RECRUITING	2026-01-01	NCT05395624
Il-Yang Pharm. Co., Ltd.	Radotinib HCl 50 mg	—	RECRUITING	2025-12-31	NCT04691661
iRegene Therapeutics Co., Ltd.	Human Dopaminergic Progenitor Cells	—	RECRUITING	2025-12	NCT06167681
Laboratorio Elea Phoenix S.A.	Cannabidiol 100 mg/ml	—	RECRUITING	2025-11	NCT06629389
BioArctic AB	exidavnemab	—	ACTIVE NOT RECRUITING	2026-08-17	NCT06671938
Shanghai Vitalgen BioPharma Co., Ltd.	VGN-R09b	—	ACTIVE NOT RECRUITING	2026-09-10	NCT06480461
TrueBinding, Inc.	TB006	—	ACTIVE NOT RECRUITING	2026-11-28	NCT06773962
Denali Therapeutics Inc.	BIIB122 225 mg	—	ACTIVE NOT RECRUITING	2027-03	NCT06602193
AC Immune SA	ACI-7104.056 at Dose A	—	ACTIVE NOT RECRUITING	2028-01	NCT06015841
MeiraGTx, LLC	—	—	ACTIVE NOT RECRUITING	2029-10	NCT05894343
Prevail Therapeutics	LY3884961	—	ACTIVE NOT RECRUITING	2030-12-31	NCT04127578
BioVie Inc.	NE3107	—	ACTIVE NOT RECRUITING	2026-05-01	NCT06757010
Bial R&D Investments, S.A.	BIA 28-6156 10 mg	—	ACTIVE NOT RECRUITING	2026-04-02	NCT05819359
Kissei Pharmaceutical Co., Ltd.	KDT-3594	—	ACTIVE NOT RECRUITING	2026-04	NCT06722729
Chase Therapeutics Corporation	—	—	ACTIVE NOT RECRUITING	2025-12-30	NCT03683225
FAScinate Therapeutics Inc.	KM-819	—	ACTIVE NOT RECRUITING	2025-10-30	NCT05670782
BrainX Corporation	Ceftriaxone	—	ACTIVE NOT RECRUITING	2025-07-28	NCT03413384
Roche	Prasinezumab	—	ACTIVE NOT RECRUITING	2024-09-11	NCT04777331
Aptinyx	NYX-458	—	ACTIVE NOT RECRUITING	2022-12-30	NCT04148391
Roche	RO7046015	—	ACTIVE NOT RECRUITING	2019-11-27	NCT03100149
NeuroDerm Ltd.	ND0612	—	ACTIVE NOT RECRUITING	2019-09-09	NCT02726386
iRegene Therapeutics Co., Ltd.	Human Dopaminergic Progenitor Cells	—	NOT YET RECRUITING	2026-12	NCT07028632
Shanghai Vitalgen BioPharma Co., Ltd.	VGN-R08b 4.2×10^13 vg	—	NOT YET RECRUITING	2027-09-01	NCT07414290
AskBio Inc	AB-1005	—	NOT YET RECRUITING	2027-12-30	NCT07215403
Qilu Pharmaceutical Co., Ltd.	GM1	—	NOT YET RECRUITING	2028-03	NCT07585565
Gain Therapeutics, Inc.	Low Dose GT-02287	—	NOT YET RECRUITING	2028-06-30	NCT07280299
Forest Hills Lab	Gemfibrozil	Peroxisome Proliferator Receptor alpha Agonist [EPC]	NOT YET RECRUITING	2028-11-01	NCT05931484
Biocells Medical	Intrathecal (IT)	—	NOT YET RECRUITING	2028-11-23	NCT07471230
Bayer	AB-1005	—	NOT YET RECRUITING	2028-12-15	NCT07566429
H. Lundbeck A/S	Lu AF28996	—	NOT YET RECRUITING	2028-12-30	NCT07514858
Energenesis Biomedical Co., Ltd.	ENERGI-F705 Tablets	—	NOT YET RECRUITING	2030-01-01	NCT07647614
InnoMedica Schweiz AG	Talineuren	—	NOT YET RECRUITING	2025-11	NCT06431971
Mthera Pharma Co., Ltd.	MT101-5	—	NOT YET RECRUITING	2025-07	NCT06175767
Biogen	BIIB122	—	COMPLETED	2026-03-09	NCT05348785
Glaceum	Vutiglabridin	—	COMPLETED	2025-12-16	NCT06329141
S.Biomedics Co., Ltd.	Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC) Low Dose	—	COMPLETED	2025-12-10	NCT05887466
Intra-Cellular Therapies, Inc.	Lenrispodun	—	COMPLETED	2025-10-28	NCT05766813
Hope Biosciences Research Foundation	Biological/Vaccine: Allogeneic HB-adMSCs	—	COMPLETED	2025-10-03	NCT04995081
Zomagen Biosciences Ltd.	VTX3232	—	COMPLETED	2025-04-04	NCT06556173
UCB Biopharma SRL	UCB0022	—	COMPLETED	2025-03-31	NCT06055985
Cerevance Beta, Inc.	CVN424 150 mg	—	COMPLETED	2025-01-30	NCT06006247
Celon Pharma SA	CPL500036 - low dose	—	COMPLETED	2025-01-13	NCT05297201
Integrative Research Laboratories AB	Pirepemat	—	COMPLETED	2024-12-04	NCT05258071
ABLi Therapeutics, Inc.	IkT-148009 (risvodetinib)	—	COMPLETED	2024-10-25	NCT05424276
Jazz Pharmaceuticals	Suvecaltamide	—	COMPLETED	2024-10-23	NCT05642442
UCB Biopharma SRL	UCB0599	—	COMPLETED	2024-09-06	NCT04658186
MeiraGTx, LLC	—	—	COMPLETED	2024-09-06	NCT05603312
SNLD, Ltd.	TR-012001	—	COMPLETED	2024-04-26	NCT06212089
Jiangsu HengRui Medicine Co., Ltd.	HRG2010(I)	—	COMPLETED	2024-01-31	NCT06614153
Supernus Pharmaceuticals, Inc.	SAGE-718	—	COMPLETED	2024-01-17	NCT05318937
Amydis Inc.	AMDX2011P	—	COMPLETED	2023-03-15	NCT05542576
Takeda	TAK-071	—	COMPLETED	2023-02-27	NCT04334317
Neuraly, Inc.	NLY01	—	COMPLETED	2023-02-14	NCT04154072
Hope Biosciences Research Foundation	HB-adMSCs	—	COMPLETED	2023-02-06	NCT04928287
Integrative Research Laboratories AB	Mesdopetam	—	COMPLETED	2022-12-02	NCT04435431
BioVie Inc.	NE3107	—	COMPLETED	2022-11-21	NCT05083260
SynAgile Corporation	—	—	COMPLETED	2022-07-21	NCT04778176
CuraSen Therapeutics, Inc.	clenbuterol (CST-103), nadolol (CST-107), matching placebo	—	COMPLETED	2022-07-04	NCT04739423
Anavex Life Sciences Corp.	ANAVEX2-73	—	COMPLETED	2022-05-31	NCT04575259
Supernus Pharmaceuticals, Inc.	SAGE-718	—	COMPLETED	2022-03-25	NCT04476017
Stoparkinson Healthcare Systems LLC	—	—	COMPLETED	2022-01-05	NCT04652583
Enterin Inc.	Active Investigational Treatment ENT-01	—	COMPLETED	2021-12-14	NCT03781791
Eisai Inc.	E2027	—	COMPLETED	2021-12-08	NCT04764669
Cerevance Beta, Inc.	CVN424 Low Dose	—	COMPLETED	2021-11-06	NCT04191577
Kissei Pharmaceutical Co., Ltd.	KDT-3594	—	COMPLETED	2021-09-06	NCT04867551
Annovis Bio Inc.	Posiphen	—	COMPLETED	2021-08-16	NCT04524351
Clene Nanomedicine	Gold Nanocrystals	—	COMPLETED	2021-06-07	NCT03815916
Alkahest, Inc.	AKST4290	—	COMPLETED	2021-02-11	NCT04369430
Anavex Life Sciences Corp.	High dose ANAVEX2-73	—	COMPLETED	2020-09-30	NCT03774459
Alkahest, Inc.	GRF6021	—	COMPLETED	2020-07-20	NCT03713957
Herantis Pharma Plc.	Cerebral Dopamine Neurotrophic Factor	—	COMPLETED	2020-07-08	NCT03775538
Otsuka Pharmaceutical Development & Commercialization, Inc.	SEP-363856	—	COMPLETED	2020-04-20	NCT02969369
Kyowa Kirin Co., Ltd.	KW-6356	—	COMPLETED	2020-04-15	NCT03703570
Kissei Pharmaceutical Co., Ltd.	KDT-3594	—	COMPLETED	2020-02-21	NCT03845387
Prexton Therapeutics	PXT002331 - dose 1	—	COMPLETED	2020-02-19	NCT03162874
Theranexus	THN102 Dosage A	—	COMPLETED	2019-12-20	NCT03624920
Herantis Pharma Plc.	Cerebral Dopamine Neurotrophic Factor	—	COMPLETED	2019-12-19	NCT03295786
ApoPharma	Deferiprone	Iron Chelator [EPC]	COMPLETED	2019-08-02	NCT02728843
ACADIA Pharmaceuticals Inc.	Pimavanserin	—	COMPLETED	2019-07-09	NCT03482882
Integrative Research Laboratories AB	Mesdopetam (IRL790)	—	COMPLETED	2019-06-12	NCT03368170
Impel Pharmaceuticals	—	—	COMPLETED	2019-06-11	NCT03541356
BenevolentAI Bio	BEN-2001	—	COMPLETED	2019-05-28	NCT03194217
BlackThorn Therapeutics, Inc.	BTRX-246040	—	COMPLETED	2019-04-16	NCT03608371
Dong-A ST Co., Ltd.	DA-9805 45mg	—	COMPLETED	2019-04-10	NCT03189563
Sumitomo Pharma America, Inc.	APL-130277	—	COMPLETED	2019-03-05	NCT03292016
Edison Pharmaceuticals Inc	PTC-589	—	COMPLETED	2019-01-08	NCT02462603
Intra-Cellular Therapies, Inc.	ITI-214	—	COMPLETED	2018-09-06	NCT03257046

Showing 100 of 175 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Vertero Therapeutics	VT-5006	—	RECRUITING	2026-09-28	NCT07310264
Serina Therapeutics	SER-252 (PEOZ-apomorphine)	—	RECRUITING	2027-01-31	NCT07422675
Innopeutics Corporation	IPS101A	—	RECRUITING	2027-10-31	NCT07371338
Eli Lilly	LY4006896	—	RECRUITING	2028-01	NCT06809400
Prevail Therapeutics	LY3962681	—	RECRUITING	2029-05-05	NCT06565195
Regeneron	ALN-SNCA	—	RECRUITING	2029-06-07	NCT07216066
Nuwacell Biotechnologies Co., Ltd.	Allogeneic dopaminergic neural precursor cell(NCR201)	—	RECRUITING	2026-07-01	NCT06978920
Highlightll Pharmaceutical (USA) LLC	HL-400	—	RECRUITING	2026-06-30	NCT06997484
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.	human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection	—	RECRUITING	2026-04-30	NCT07080775
iRegene Therapeutics Co., Ltd.	Human Dopaminergic Progenitor Cells	—	RECRUITING	2026-04	NCT06608355
Gain Therapeutics, Inc.	GT-02287	—	RECRUITING	2025-11-30	NCT06732180
Longevity Biotech Australia Pty Ltd (subsidiary)	LBT-3627	—	RECRUITING	2025-10	NCT06466525
1ST Biotherapeutics, Inc.	FB418	—	RECRUITING	2024-12	NCT05995782
Shanghai UniXell Biotechnology Co., Ltd	UX-DA001	—	ACTIVE NOT RECRUITING	2027-12	NCT06778265
Brain Neurotherapy Bio, Inc.	AAV2-GDNF	—	ACTIVE NOT RECRUITING	2023-10-17	NCT04167540
Synusight Biotech (Shanghai) Co., Ltd.	SST001	—	NOT YET RECRUITING	2026-12	NCT07604116
H. Lundbeck A/S	Lu AF28996	—	NOT YET RECRUITING	2027-05-31	NCT07513441
Taiwan Mitochondrion Applied Technology Co., Ltd.	Aadipose-Derived Mesenchymal Stem Cells	—	NOT YET RECRUITING	2027-09-30	NCT05094011
Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.	Human-derived stromal cells	—	NOT YET RECRUITING	2027-10-10	NCT07232147
iCamuno Biotherapeutics Ltd.	ALC01 therapy	—	NOT YET RECRUITING	2027-12-15	NCT07212088
iRegene Therapeutics Co., Ltd.	NouvNeu001 injection	—	NOT YET RECRUITING	2028-04	NCT07550374
iCamuno Biotherapeutics Ltd.	ICA07 therapy	—	NOT YET RECRUITING	2025-12-30	NCT06821529
Luye Pharma Group Ltd.	LY03017	—	NOT YET RECRUITING	2025-10-31	NCT06793995
Luye Pharma Group Ltd.	LY03017	—	NOT YET RECRUITING	2025-10	NCT06980207
H. Lundbeck A/S	Lu AF28996	—	COMPLETED	2025-10-14	NCT04291859
Herantis Pharma Plc.	HER-096	—	COMPLETED	2025-08-14	NCT06659562
Cyto Therapeutics Pty Limited	ISC-hpNSC	—	COMPLETED	2025-06-18	NCT02452723
Neurocrine Biosciences	VY-AADC02	—	COMPLETED	2024-10-30	NCT03562494
SNLD, Ltd.	TRN501 - Dose 1	—	COMPLETED	2024-09-20	NCT06453551
Ionis Pharmaceuticals, Inc.	BIIB094	—	COMPLETED	2024-08-12	NCT03976349
Roche	RO7486967	—	COMPLETED	2024-07-18	NCT05924243
Guangzhou Henovcom Bioscience Co. Ltd.	HNC364	—	COMPLETED	2024-04-15	NCT05523570
Humanis Saglık Anonim Sirketi	Pimavanserin 34 mg	—	COMPLETED	2024-01-17	NCT06450184
Cerevel Therapeutics, LLC	Tavapadon	—	COMPLETED	2023-12-12	NCT05610189
H. Lundbeck A/S	Lu AF28996	—	COMPLETED	2023-11-21	NCT06004180
PureIMS B.V.	—	—	COMPLETED	2023-10-20	NCT06037590
Herantis Pharma Plc.	HER-096	—	COMPLETED	2023-09-29	NCT05915247
UCB Biopharma SRL	UCB7853	—	COMPLETED	2023-07-20	NCT04651153
BlueRock Therapeutics	MSK-DA01	—	COMPLETED	2023-05-18	NCT04802733
AbbVie	ABBV-951	—	COMPLETED	2023-03-17	NCT05094050
United Neuroscience Ltd.	UB-312	—	COMPLETED	2023-03-01	NCT04075318
UCB Biopharma SRL	UCB0022	—	COMPLETED	2023-02-27	NCT04867642
Mthera Pharma Co., Ltd.	MT101-5	—	COMPLETED	2023-02-23	NCT05844787
Cerevel Therapeutics, LLC	Tavapadon	—	COMPLETED	2023-01-27	NCT05581823
Five Eleven Pharma, Inc.	[18F]P17-059	—	COMPLETED	2022-12-19	NCT03903549
Sumitomo Pharma Co., Ltd.	DSP-9632P 27.5 mg	—	COMPLETED	2022-11-30	NCT05435729
Cerevance Beta, Inc.	CVN424	—	COMPLETED	2022-11-11	NCT05635461
MODAG GmbH	anle138b	—	COMPLETED	2022-11-07	NCT04685265
ABLi Therapeutics, Inc.	IkT-148009	—	COMPLETED	2022-10-30	NCT04350177
Sunshine Lake Pharma Co., Ltd.	HEC122505MsOH	—	COMPLETED	2022-01-06	NCT04625361
AstraZeneca	MEDI1341	—	COMPLETED	2022-01-05	NCT04449484
1ST Biotherapeutics, Inc.	FB-101	—	COMPLETED	2021-11-12	NCT04165837
Shijiazhuang Yiling Pharmaceutical Co. Ltd	Phenlarmide	—	COMPLETED	2021-10-29	NCT04693039
Bial R&D Investments, S.A.	Carbon-14 BIA 28-6156	—	COMPLETED	2021-10-16	NCT05220072
Jiangsu HengRui Medicine Co., Ltd.	HRG2010 Capsule, Sinemet®, Madopar®	—	COMPLETED	2021-10-07	NCT06976346
Neurocrine Biosciences	VY-AADC01	—	COMPLETED	2021-08-10	NCT03065192
H. Lundbeck A/S	Lu AF82422	—	COMPLETED	2021-07-26	NCT03611569
Cerevel Therapeutics, LLC	CVL-751	—	COMPLETED	2021-07-23	NCT04295642
Luye Pharma Group Ltd.	LY03003	—	COMPLETED	2021-05-12	NCT04630860
AstraZeneca	MEDI1341	—	COMPLETED	2021-03-31	NCT03272165
Biogen	DNL151	—	COMPLETED	2020-12-02	NCT04056689
Yiling Pharmaceutical Inc.	Phenlarmide Tablets	—	COMPLETED	2020-12-02	NCT04164121
Kyowa Kirin Co., Ltd.	KW-6356	—	COMPLETED	2020-09-05	NCT04342273
Luye Pharma Group Ltd.	LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)	—	COMPLETED	2020-08-05	NCT04384666
UCB Biopharma S.P.R.L.	UCB0599	—	COMPLETED	2020-02-19	NCT04875962
Neurocrine Biosciences	VY-AADC01	—	COMPLETED	2020-01-24	NCT01973543
Denali Therapeutics Inc.	DNL201	—	COMPLETED	2019-12-06	NCT03710707
Collaborative Medicinal Development Pty Limited	Cu(II)ATSM	—	COMPLETED	2019-11-30	NCT03204929
Kyowa Kirin Co., Ltd.	KW-6356	—	COMPLETED	2019-11-19	NCT04070495
Kyowa Kirin Co., Ltd.	KW-6356 Low Dose	—	COMPLETED	2019-10-10	NCT03830528
Kyowa Kirin Co., Ltd.	Midazolam	Benzodiazepine [EPC]	COMPLETED	2019-07-31	NCT03970798
Acorda Therapeutics	CVT-301	—	COMPLETED	2019-06-28	NCT03887884
Bial - Portela C S.A.	Ongentys	Catechol-O-Methyltransferase Inhibitor [EPC]	COMPLETED	2019-06-09	NCT03820037
AbbVie	ABBV-951	—	COMPLETED	2019-06-08	NCT03033498
Sun Pharma Advanced Research Company Limited	K0706	—	COMPLETED	2019-05-28	NCT02970019
Luye Pharma Group Ltd.	LY03003 ( Rotigotine, extended-release microspheres)	—	COMPLETED	2019-04-16	NCT04045678
Luye Pharma Group Ltd.	LY03003	—	COMPLETED	2019-03-14	NCT04629404
AbbVie	ABBV-951	—	COMPLETED	2019-03-04	NCT03374917
Luye Pharma Group Ltd.	LY03003	—	COMPLETED	2018-12-23	NCT03733561
Luye Pharma Group Ltd.	LY03003	—	COMPLETED	2018-10-31	NCT03589066
Kissei Pharmaceutical Co., Ltd.	KDT-3594	—	COMPLETED	2018-08-13	NCT03068481
Bial - Portela C S.A.	50 mg BIA 9 1067	—	COMPLETED	2018-07-24	NCT04265027
Neurocrine Biosciences	Opicapone	Catechol-O-Methyltransferase Inhibitor [EPC]	COMPLETED	2018-07-02	NCT03496870
Yiling Pharmaceutical Inc.	Finamine tablets	—	COMPLETED	2018-04-27	NCT04162275
Biogen	BIIB054	—	COMPLETED	2017-11-20	NCT02459886
Kainos Medicine Inc.	KM-819	—	COMPLETED	2017-09	NCT03022799
Bial - Portela C S.A.	Opicapone (OPC)	—	COMPLETED	2017-08-28	NCT03116295
Orion Corporation, Orion Pharma	Levodopa, carbidopa, ODM-104	—	COMPLETED	2017-07-03	NCT03140956
Bial - Portela C S.A.	[14C]-BIA 9-1067	—	COMPLETED	2017-04-27	NCT03119194
Eli Lilly	LY3154207	—	COMPLETED	2017-03-03	NCT02562768
Affiris AG	AFFITOPE® PD01A	—	COMPLETED	2017-02-28	NCT02618941
H. Lundbeck A/S	0.04 mg Lu AE04621	—	COMPLETED	2016-12	NCT02649608
Beijing Pins Medical Co., Ltd	—	—	COMPLETED	2016-12	NCT02601144
Acorda Therapeutics	CVT-301, LIP	—	COMPLETED	2016-11	NCT02807675
Prothena Biosciences Limited	PRX002	—	COMPLETED	2016-09	NCT02157714
Luye Pharma Group Ltd.	ROTIGOTINE	Nonergot Dopamine Agonist [EPC]	COMPLETED	2016-08	NCT02728947
Affiris AG	Low dose AFFITOPE® PD03A + Adjuvant	—	COMPLETED	2016-08	NCT02267434
Acorda Therapeutics	CVT-301 (Dose Level 1)	—	COMPLETED	2016-08	NCT02812394
Prexton Therapeutics	PXT002331	—	COMPLETED	2016-08	NCT02639221
NeuroDerm Ltd.	ND0612	—	COMPLETED	2016-06-30	NCT02604914

Novel Parkinson's Disease Drugs by Company (New molecular entities)

3 companies have an FDA-approved novel drug for Parkinson's Disease.

KYOWA KIRIN 1 drug

AMNEAL 1 drug

UCB INC 1 drug

Reformulations (23 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.